Supplemental Table 6 from Validating Wave 1 (2014) urinary cotinine and TNE-2 cut-points for differentiating Wave 4 (2017) cigarette use from non-use in the US using data from the PATH Study.

Cite This Study

Edwards et al. (2024) studied this question.

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1Supplemental Table 6 from Validating Wave 1 (2014) urinary cotinine and TNE-2 cut-points for differentiating Wave 4 (2017) cigarette use from non-use in the US using data from the PATH Study.2024
2Supplemental Table 5 from Validating Wave 1 (2014) urinary cotinine and TNE-2 cut-points for differentiating Wave 4 (2017) cigarette use from non-use in the US using data from the PATH Study.2024
3Supplemental Table 5 from Validating Wave 1 (2014) urinary cotinine and TNE-2 cut-points for differentiating Wave 4 (2017) cigarette use from non-use in the US using data from the PATH Study.2024
4Supplemental Table 4 from Validating Wave 1 (2014) urinary cotinine and TNE-2 cut-points for differentiating Wave 4 (2017) cigarette use from non-use in the US using data from the PATH Study.2024
5Supplemental Table 4 from Validating Wave 1 (2014) urinary cotinine and TNE-2 cut-points for differentiating Wave 4 (2017) cigarette use from non-use in the US using data from the PATH Study.2024

View at Publisher

Ask AI

Bookmark

Share

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: